One-click Automated 3D Treatment Planning for Radiopharmaceutical Therapy

用于放射性药物治疗的一键式自动化 3D 治疗计划

• 批准号: 10678173
• 负责人: Joseph Grudzinski
• 金额: $ 200万
• 依托单位: VOXIMETRY, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10678173
• 关键词: 3-Dimensional; Acceleration; Address; Adoption; Algorithms; Antibodies; Artificial Intelligence; Automation; Benchmarking; Biodistribution; Calibration; Cancer Patient; Characteristics; Clinic; Clinical; Computer software; Consensus; Contracts; Deposition; Development; Disseminated Malignant Neoplasm; Dose; Drug Kinetics; Ensure; Evaluation; External Beam Radiation Therapy; Funding; Gamma Rays; Goals; Grant; Healthcare Systems; Image; Intellectual Property; Lead; Lymphoma; Marketing; Metastatic Prostate Cancer; Methods; Modeling; Neoplasm Metastasis; Neuroendocrine Tumors; Normal tissue morphology; Organ; Overdose; Patient-Focused Outcomes; Patients; Peptides; Pharmaceutical Preparations; Phase; Physicians; Physiology; Radiation; Radioactivity; Radioisotopes; Radiopharmaceuticals; Reporting; Resources; Risk; Route; Secure; Small Business Innovation Research Grant; System; Technology; Testing; Therapeutic; Time; Treatment outcome; Tumor Tissue; Validation; Work; absorption; automated segmentation; cancer therapy; chemotherapy; clinical decision support; clinical practice; clinically significant; commercialization; cost effective; design; digital; dosimetry; experience; image registration; individual patient; individualized medicine; neoplastic cell; personalized medicine; pharmacokinetic model; reconstruction; response; side effect; single photon emission computed tomography; small molecule; theranostics; tool; treatment planning; tumor; uptake; user-friendly; verification and validation

PROJECT SUMMARY/ABSTRACT The Radiopharmaceutical Therapy (RPT) market is projected to surpass the Technitium-99m market by 2025, with an emphasis on metastatic prostate cancer, neuroendocrine tumors, and lymphoma. Driven by well- tolerated treatments and fewer side-effects, experts have estimated 150 new theranostic centers will be needed in the U.S. to deliver an estimated 50,000–200,000 treatment cycles/year. Currently, all RPT treatments administer a standard therapeutic dose despite unique patient physiology and pharmacokinetics. From experience with external beam radiation therapy (EBRT), we know that patient-specific prescriptions based on absorbed dose leads to better patient outcomes. A key technology required to enable this personalization is fast, accurate, whole-body patient-specific dosimetry. In a prior Phase II SBIR, Voximetry was able to integrate our fully benchmarked and IP-protected Monte Carlo dosimetry algorithm into a cost-effective RPT treatment planning solution (TorchTM) by adding additional features such as image registration, contour propagation, and voxel-based pharmacokinetic (PK) modeling. Torch was designed to model uptake and clearance routes of any drug class (e.g., small molecules, peptides, antibodies) and any radionuclide, effectively adding a ‘swiss army knife’ tool into the clinician’s RPT toolkit. Leveraging the gamma rays emitted by the RPT agent, Torch can calculate how much radiation energy is deposited within each voxel of organs and tumors throughout the body. Estimates of voxel-level whole-body patient-specific dosimetry are better correlated with response than the standard uptake value (SUV) information that is clinically available today. Using this approach, Voximetry has developed a fast, accurate, RPT treatment planning solution aimed to inform clinicians with extremely accurate voxel-based Monte Carlo (MC) dosimetry in a matter of minutes. Additionally, Vox has developed a GPU accelerated Monte Carlo SPECT reconstruction algorithm that leads to dosimetry estimates which differ from conventional reconstruction algorithms by at least 25%, which is seen as clinically significant. This information will support clinical decisions to personalize safe therapeutic doses. Automation of this RPT dosimetry workflow is especially important for healthcare systems that would like to implement dosimetry-guided therapy in clinical practice but are currently ill-equipped in terms of expertise and resources to perform advanced dosimetry for RPT. By enabling automation, Vox will ultimately benefit cancer patients by making available a personalized treatment that targets metastatic cancer that in many cases is more efficacious and has fewer side effects than chemotherapy. The specific aims that will be accomplished in the proposal are to (1) Develop automated segmentation tools for organs and risk and tumors using artificial intelligence, (2) develop scanner calibration, partial volume correction, and Monte Carlo reconstruction to ensure accurate SPECT imaging, and (3) automate, implement, and validate end-to-end clinical Torch workflow. The successful completion of these aims will help break down barriers to commercialization and accelerate market adoption of Torch.

项目摘要/摘要 放射性药物治疗（RPT）市场预计将于2025年超过99m市场 重点是前列腺癌，神经内分泌肿瘤和淋巴瘤。由良好驱动 耐受的治疗和较少的副作用，专家估计需要150个新的Theranotic中心 在美国，估计每年提供50,000–200,000个治疗周期。目前，所有RPT治疗 管理标准的治疗剂量目的地独特的患者生理和药代动力学。从 具有外束放射治疗（EBRT）的经验，我们知道基于患者的处方 实现这种个性化所需的关键技术很快， 准确的全身患者特异性剂量法。在先前的II阶段SBIR中，Voximetry能够整合我们的 完全基准的和受IP的蒙特卡洛剂量法算法成本有效的RPT处理 通过添加其他功能，例如图像注册，轮廓传播和 基于体素的药代动力学（PK）建模。火炬旨在模拟任何任何的吸收和清除路线 毒品类（例如，小分子，肽，抗体）和任何放射线，有效地增加了'瑞士军队 刀的工具进入临床的RPT工具包。利用RPT代理发出的伽马射线，Torch Can 计算整个器官和肿瘤的每个体素中沉积多少辐射能。 体素级全身患者特异性剂量法的估计比反应更好 当今临床上可用的标准吸收值（SUV）信息。使用这种方法，紫氧 开发了一种快速，准确的RPT治疗计划解决方案，旨在以极为准确的方式告知临床医生 在几分钟之内，基于体素的蒙特卡洛（MC）剂量法。此外，Vox开发了GPU 加速的蒙特卡洛频谱重建算法，导致剂量计估计值不同 常规重建算法至少为25％，这被视为临床意义。此信息 将支持个性化安全治疗剂量的临床决定。此RPT剂量学工作流的自动化 对于希望在临床中实施剂量学引导疗法的医疗系统尤其重要 练习，但目前在专业知识和资源方面做得不足，以执行高级剂量法 RPT。通过启用自动化，Vox最终将通过提供个性化来使癌症患者受益 针对转移性癌症的治疗方法在许多情况下更有效，副作用比 化学疗法。提案中将实现的具体目的是（1）发展自动化 使用人工智能的器官和风险和肿瘤的分割工具，（2）开发扫描仪校准， 部分体积校正和蒙特卡洛重建以确保精确的SPECT成像，（3）自动化 实施并验证端到端的临床火炬工作流程。这些目标的成功完成将有助于 打破商业化的障碍，并加速割炬的市场采用。